When was PEARKO Therapeutics founded?

PEARKO Therapeutics was founded in 2013.

Where is PEARKO Therapeutics located?

PEARKO Therapeutics is headquartered in Edmonton, Canada.

How many employees does PEARKO Therapeutics have?

As of Apr 30, 2026, the latest employee count at PEARKO Therapeutics is 1.

Is PEARKO Therapeutics a funded company?

PEARKO Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does PEARKO Therapeutics rank among its competitors?

PEARKO Therapeutics ranks 9th amongst 11 active competitors, of which 7 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Retension Pharmaceuticals, which secured $15M in Apr, 2025.

Who are the top competitors of PEARKO Therapeutics?

PEARKO Therapeutics' top competitors include Mineralys Therapeutics, Retension Pharmaceuticals and Zymedi. Among them, Retension Pharmaceuticals secured the most recent funding round in April, 2025.

PEARKO Therapeutics - 2026 Company Profile, Team & Competitors

PEARKO Therapeutics is an unfunded company based in Edmonton (Canada), founded in 2013 by Gavin Y Oudit and John C Vederas. It operates as a Develope of pharmacological therapies for cardiovascular diseases. PEARKO Therapeutics has not raised any funding yet. The company has 11 active competitors, including 7 funded and 1 that has exited. Its top competitors include companies like Mineralys Therapeutics, Retension Pharmaceuticals and Zymedi.

Company Details

PEARKO Therapeutics is developing pharmacological therapies for cardiovascular diseases. The company currently two ongoing projects angiotensin 1-7 analog, and ADAM 17 inhibition which is for blood pressure management. Its apelin is the natural endogenous peptide that can regulate angiogenesis, blood flow, blood pressure, and cardiac contractility.

Website: pearkotherapeutics.com
Email ID: *****@pearkotherapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2013

Location

Edmonton, Canada

Stage

Unfunded

Ranked

9^th among 11 active competitors

Employee Count

1 as on Apr 30, 2026

Similar Companies

Mineralys Therapeutics & 12 more

View PEARKO Therapeutics' full profile

PEARKO Therapeutics has not raised any funding rounds yet.

The founders of PEARKO Therapeutics are Gavin Y Oudit and John C Vederas.

Here are the details of PEARKO Therapeutics' key team members:

Gavin Y Oudit: Founder of PEARKO Therapeutics.
Contact Info: 1 email address
John C Vederas: Co-Founder of PEARKO Therapeutics.

View details of PEARKO Therapeutics's Founder profiles and Board Members

PEARKO Therapeutics' employee count trend

PEARKO Therapeutics has 1 employees as of Apr 26. Here is PEARKO Therapeutics's employee count trend over the years:

Employee count trend for PEARKO Therapeutics

Uncover PEARKO Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PEARKO Therapeutics include Mineralys Therapeutics, Retension Pharmaceuticals and Zymedi. Here is the list of Top 10 competitors of PEARKO Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Mineralys Therapeutics 2020, Radnor (United States), Public	Developer of therapy for the treatment of hypertension	$158M	Andera Partners, HBM Healthcare Investments ... & 15 others	61/100
2nd	Retension Pharmaceuticals 2023, Falls Church (United States), Series B	Developer of treatments for hypertension and cardiovascular diseases	$25.4M	Collage Venture Partners	51/100
3rd	Zymedi 2019, Incheon (South Korea), Series A	Developer of therapeutics for multiple diseases	$29.5M	Company K Partners, KVIC & 6 others	40/100
4th	Autotelic Bio 2015, South Korea, Series B	Developer of therapeutics for cancer treatment	$18.2M	UTC Investment, Solidus Investment & 12 others	39/100
5th	Retension Pharmaceuticals 2023, Mclean (United States), Series B	Developer of pharmaceutical treatments for hypertension and cardiovascular diseases	$10.1M	-	32/100
6th	Morphogen-IX 2015, Cambridge (United Kingdom), Series B	Provider of therapeutics for pulmonary arterial hypertension (PAH)	$25.3M	Medicxi, Cambridge Enterprise & 2 others	27/100
7th	Avirmax 2019, Hayward (United States), Funding Raised	Developer of rAAV mediated gene therapies	-	3E Bioventures Capital	26/100
8th	Linnet Biopharmaceuticals 2010, New York City (United States), Seed	Developer of drugs for cardiac health	$25K	-	24/100
9th	PEARKO Therapeutics 2013, Edmonton (Canada), Unfunded	Develope of pharmacological therapies for cardiovascular diseases	-	-	22/100
10th	Ridge Therapeutics 2017, Lake Bluff (United States), Deadpooled	Reformulation and redevelopment of existing drugs	-	-	23/100